Published in Cancer Res on December 01, 2005
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol (2011) 4.12
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol (2010) 2.93
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A (2006) 2.86
ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest (2007) 2.78
HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res (2006) 2.74
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A (2011) 2.18
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies. Expert Rev Anticancer Ther (2011) 1.92
Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab. PLoS One (2009) 1.91
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther (2008) 1.88
Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res (2009) 1.86
Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther (2011) 1.84
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol (2013) 1.81
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog (2012) 1.75
Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol (2010) 1.68
HER2: biology, detection, and clinical implications. Arch Pathol Lab Med (2011) 1.68
Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res (2008) 1.67
IGF-1 receptor inhibitors in clinical trials--early lessons. J Mammary Gland Biol Neoplasia (2008) 1.62
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol (2008) 1.58
Targeting insulin-like growth factor pathways. Br J Cancer (2006) 1.57
Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer (2010) 1.56
LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol (2006) 1.55
Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res (2008) 1.50
Roles for growth factors in cancer progression. Physiology (Bethesda) (2010) 1.48
Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer (2012) 1.48
Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res (2012) 1.47
Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res (2009) 1.44
Retracted Targeting 3-phosphoinoside-dependent kinase-1 to inhibit insulin-like growth factor-I induced AKT and p70 S6 kinase activation in breast cancer cells. PLoS One (2012) 1.41
HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther (2008) 1.40
Insulin growth factor 1 like receptor (IGF-1R). BMC Cancer (2016) 1.38
Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol Cancer Res (2012) 1.33
Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res (2010) 1.32
Estrogen signaling via a linear pathway involving insulin-like growth factor I receptor, matrix metalloproteinases, and epidermal growth factor receptor to activate mitogen-activated protein kinase in MCF-7 breast cancer cells. Endocrinology (2007) 1.32
IGF-1R as an anti-cancer target--trials and tribulations. Chin J Cancer (2013) 1.31
Trastuzumab and breast cancer: developments and current status. Int J Clin Oncol (2006) 1.30
The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat (2009) 1.29
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle (2009) 1.29
Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. Cancer Res (2008) 1.26
Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev (2012) 1.23
Targeting of erbB3 receptor to overcome resistance in cancer treatment. Mol Cancer (2014) 1.22
Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor. Exp Cell Res (2007) 1.22
Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int (2014) 1.21
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer. Breast Cancer Res (2009) 1.20
The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies. Exp Mol Pathol (2009) 1.18
Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function. Clin Cancer Res (2012) 1.17
Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci Signal (2013) 1.17
HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer (2014) 1.14
The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am (2012) 1.14
Her2 cross talk and therapeutic resistance in breast cancer. Front Biosci (2008) 1.14
Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer. Br J Cancer (2012) 1.12
Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells. Biochem Pharmacol (2011) 1.12
Nordihydroguaiaretic acid, a cytotoxic insulin-like growth factor-I receptor/HER2 inhibitor in trastuzumab-resistant breast cancer. Mol Cancer Ther (2008) 1.12
Pharmacological strategies to overcome HER2 cross-talk and Trastuzumab resistance. Curr Med Chem (2012) 1.12
Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers. Mol Cell Proteomics (2012) 1.10
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. Int J Breast Cancer (2011) 1.10
Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays. Oncogene (2012) 1.10
Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines. Clin Cancer Res (2009) 1.10
Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem (2009) 1.10
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med (2014) 1.09
Cixutumumab. Expert Opin Investig Drugs (2009) 1.09
Targeting insulin and insulin-like growth factor signaling in breast cancer. J Mammary Gland Biol Neoplasia (2012) 1.08
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma. Mol Cancer Ther (2011) 1.07
Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies. PLoS One (2009) 1.05
Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer. Ann Oncol (2012) 1.05
Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol (2009) 1.04
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells. Oncogene (2013) 1.04
Lapatinib induces autophagy, apoptosis and megakaryocytic differentiation in chronic myelogenous leukemia K562 cells. PLoS One (2011) 1.04
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer. Mol Cancer (2014) 1.03
A cross-talk between TrkB and Ret tyrosine kinases receptors mediates neuroblastoma cells differentiation. PLoS One (2008) 1.03
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Med Wochenschr (2010) 1.02
Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget (2016) 1.00
In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother Pharmacol (2009) 1.00
Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling. Oncogene (2013) 0.99
A candidate targeting molecule of insulin-like growth factor-I receptor for gastrointestinal cancers. World J Gastroenterol (2010) 0.99
Strong EGFR signaling in cell line models of ERBB2-amplified breast cancer attenuates response towards ERBB2-targeting drugs. Oncogenesis (2012) 0.99
Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens. Curr Pharmacogenomics Person Med (2009) 0.99
Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients. Proteome Sci (2011) 0.98
Targeting the Insulin-Like Growth Factor 1 Receptor in Ewing's Sarcoma: Reality and Expectations. Sarcoma (2011) 0.98
HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer. Anticancer Res (2007) 0.96
HER2 and HER3 cooperatively regulate cancer cell growth and determine sensitivity to the novel investigational EGFR/HER2 kinase inhibitor TAK-285. Oncoscience (2014) 0.96
HER2 therapies and gastric cancer: a step forward. World J Gastroenterol (2013) 0.96
IQGAP1 protein binds human epidermal growth factor receptor 2 (HER2) and modulates trastuzumab resistance. J Biol Chem (2011) 0.96
Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochim Biophys Acta (2014) 0.96
Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer (2014) 0.95
Notch-EGFR/HER2 Bidirectional Crosstalk in Breast Cancer. Front Oncol (2014) 0.94
Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma. Br J Cancer (2014) 0.93
The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Mol Cancer (2013) 0.93
Dimerization in protein kinase signaling. J Biol (2006) 0.93
Selective disruption of insulin-like growth factor-1 (IGF-1) signaling via phosphoinositide-dependent kinase-1 prevents the protective effect of IGF-1 on human cancer cell death. J Biol Chem (2009) 0.92
Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad? Invest New Drugs (2012) 0.92
Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer. ISRN Oncol (2012) 0.92
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer. Breast Cancer Res (2007) 0.91
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells. BMC Cancer (2007) 0.91
Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance. Chemother Res Pract (2012) 0.91
Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth factor receptor 2 inhibitor AZD4547 in FGFR2 amplified gastric cancer. Oncotarget (2015) 0.90
Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance. Cancers (Basel) (2011) 0.90
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013. Nucleic Acids Res (2013) 6.17
IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell (2004) 6.13
Characterization of the human heart mitochondrial proteome. Nat Biotechnol (2003) 5.66
A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature (2005) 5.13
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity. J Biol Chem (2007) 4.60
Feature extraction and quantification for mass spectrometry in biomedical applications using the mean spectrum. Bioinformatics (2005) 4.26
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology (2009) 4.08
Cohort Profile: The China Health and Nutrition Survey--monitoring and understanding socio-economic and health change in China, 1989-2011. Int J Epidemiol (2009) 4.08
Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome data. Proc Natl Acad Sci U S A (2011) 3.80
CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat Cell Biol (2006) 3.49
Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell (2003) 3.42
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol (2006) 3.34
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst (2008) 3.17
Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest (2011) 2.99
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol (2012) 2.98
CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol Cell (2002) 2.92
SHREC, an effector complex for heterochromatic transcriptional silencing. Cell (2007) 2.90
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res (2007) 2.89
Distinct roles of HDAC complexes in promoter silencing, antisense suppression and DNA damage protection. Nat Struct Mol Biol (2007) 2.87
The Drosophila BMP type II receptor Wishful Thinking regulates neuromuscular synapse morphology and function. Neuron (2002) 2.79
Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res (2005) 2.76
HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res (2006) 2.74
Herceptin: mechanisms of action and resistance. Cancer Lett (2006) 2.67
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res (2004) 2.64
P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res (2004) 2.48
Tyrosine phosphorylation controls PCNA function through protein stability. Nat Cell Biol (2006) 2.45
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
L2DTL/CDT2 interacts with the CUL4/DDB1 complex and PCNA and regulates CDT1 proteolysis in response to DNA damage. Cell Cycle (2006) 2.37
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol (2011) 2.32
Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes. Clin Cancer Res (2009) 2.22
Ubiquitin ligase component Cul4 associates with Clr4 histone methyltransferase to assemble heterochromatin. Nat Cell Biol (2005) 2.21
Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J (2003) 2.11
Drosophila spastin regulates synaptic microtubule networks and is required for normal motor function. PLoS Biol (2004) 2.10
Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood (2006) 2.06
Polycomb repressive complex 2 regulates normal development of the mouse heart. Circ Res (2011) 2.05
Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-i receptor in breast cancer cells resistant to herceptin. Cancer Res (2010) 1.94
The Set1 methyltransferase opposes Ipl1 aurora kinase functions in chromosome segregation. Cell (2005) 1.94
Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors. Clin Cancer Res (2003) 1.94
Global analysis of protein damage by the lipid electrophile 4-hydroxy-2-nonenal. Mol Cell Proteomics (2008) 1.89
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther (2007) 1.85
Early breast cancer. Lancet (2009) 1.82
Eighteen year weight trajectories and metabolic markers of diabetes in modernising China. Diabetologia (2014) 1.81
Microarray analysis of chitin elicitation in Arabidopsis thaliana. Mol Plant Pathol (2002) 1.80
A randomized, multicenter study comparing the safety and efficacy of sodium phosphate tablets with 2L polyethylene glycol solution plus bisacodyl tablets for colon cleansing. Am J Gastroenterol (2007) 1.74
A novel antiapoptotic role for alpha1-antitrypsin in the prevention of pulmonary emphysema. Am J Respir Crit Care Med (2006) 1.72
Diet and nutrient intakes and risk of non-Hodgkin's lymphoma in Connecticut women. Am J Epidemiol (2004) 1.71
Splicing and transcription-associated proteins PSF and p54nrb/nonO bind to the RNA polymerase II CTD. RNA (2002) 1.71
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell (2010) 1.71
Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer. J Mammary Gland Biol Neoplasia (2008) 1.70
A specific protein substrate for a deubiquitinating enzyme: Liquid facets is the substrate of Fat facets. Genes Dev (2002) 1.66
Comparative analyses of the three-dimensional structures and enzymatic properties of alpha, beta, gamma and delta isoforms of Ca2+-calmodulin-dependent protein kinase II. J Biol Chem (2004) 1.63
Protein identification using customized protein sequence databases derived from RNA-Seq data. J Proteome Res (2011) 1.62
Community proteogenomics highlights microbial strain-variant protein expression within activated sludge performing enhanced biological phosphorus removal. ISME J (2008) 1.60
Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol (2009) 1.59
Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control (2004) 1.59
Gene expression profiling in human preadipocytes and adipocytes by microarray analysis. J Nutr (2004) 1.57
Characterization of human RNA polymerase III identifies orthologues for Saccharomyces cerevisiae RNA polymerase III subunits. Mol Cell Biol (2002) 1.55
Sodium intake from various time frames and incident hypertension among Chinese adults. Epidemiology (2013) 1.55
Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist (2009) 1.53
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer (2011) 1.53
ISWI remodeling complexes in Xenopus egg extracts: identification as major chromosomal components that are regulated by INCENP-aurora B. Mol Biol Cell (2002) 1.53
L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes. Cell Cycle (2006) 1.53
Understanding the characteristics of mass spectrometry data through the use of simulation. Cancer Inform (2005) 1.52
Understanding the patterns and trends of sodium intake, potassium intake, and sodium to potassium ratio and their effect on hypertension in China. Am J Clin Nutr (2013) 1.50
Oxidative damage to mitochondrial complex I due to peroxynitrite: identification of reactive tyrosines by mass spectrometry. J Biol Chem (2003) 1.50
Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis. Eur J Haematol (2015) 1.48
The subunit composition of the human NADH dehydrogenase obtained by rapid one-step immunopurification. J Biol Chem (2003) 1.48
Protein components of mitochondrial DNA nucleoids in higher eukaryotes. Mol Cell Proteomics (2003) 1.48
Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res (2009) 1.48
A comparison between ribo-minus RNA-sequencing and polyA-selected RNA-sequencing. Genomics (2010) 1.47
Polymorphisms in DNA repair genes and risk of non-Hodgkin lymphoma among women in Connecticut. Hum Genet (2006) 1.47
Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res (2005) 1.45
Supervised principal component analysis for gene set enrichment of microarray data with continuous or survival outcomes. Bioinformatics (2008) 1.45
Expanded coverage of the human heart mitochondrial proteome using multidimensional liquid chromatography coupled with tandem mass spectrometry. J Proteome Res (2004) 1.44
Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther (2012) 1.44
Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am J Respir Crit Care Med (2008) 1.44
Steps to ensure accuracy in genotype and SNP calling from Illumina sequencing data. BMC Genomics (2012) 1.44
Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene (2005) 1.43
Distinct transcriptomes define rostral and caudal serotonin neurons. J Neurosci (2010) 1.43
HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res (2003) 1.42
Retrograde Gbb signaling through the Bmp type 2 receptor wishful thinking regulates systemic FMRFa expression in Drosophila. Development (2003) 1.42
DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight. Nucleic Acids Res (2008) 1.42
An integrated approach for the analysis of biological pathways using mixed models. PLoS Genet (2008) 1.40
Her2-positive breast cancer: herceptin and beyond. Eur J Cancer (2008) 1.39
Peritoneal and subperitoneal stroma may facilitate regional spread of ovarian cancer. Clin Cancer Res (2005) 1.39
Screening active anti-breast cancer compounds from Cortex Magnolia officinalis by 2D LC-MS. J Sep Sci (2013) 1.39
Environmental adaptation: genomic analysis of the piezotolerant and psychrotolerant deep-sea iron reducing bacterium Shewanella piezotolerans WP3. PLoS One (2008) 1.38
Alp13, an MRG family protein, is a component of fission yeast Clr6 histone deacetylase required for genomic integrity. EMBO J (2003) 1.35
A bioinformatics workflow for variant peptide detection in shotgun proteomics. Mol Cell Proteomics (2011) 1.34
Co-expression module analysis reveals biological processes, genomic gain, and regulatory mechanisms associated with breast cancer progression. BMC Syst Biol (2010) 1.33
Recombinant T cell receptor ligand treats experimental stroke. Stroke (2009) 1.33
Mechanism of evenness interrupted (Evi)-exosome release at synaptic boutons. J Biol Chem (2012) 1.32